GleamWall
中文EN

AIM AIM ImmunoTech Inc.

Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 946644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-18.8%
TTM net income YoY10.3%
TTM EPS YoY93.4%
Revenue 3-yr CAGR-22.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,800.0%
Net margin-15,526.4%
FCF margin—
EBITDA margin-11,853.8%

Returns

ROE-2,828.6%
ROA-185.4%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets27.4%
Debt / equity0.41x
Current ratio2.75x
Interest coverage-9.33x

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$22,000$26,000$22,000$21,000$26,000$25,000$16,000$45,000
R&D expense$846,000$589,000$482,000$1.06M$607,000$1.17M$1.08M$1.66M
SG&A expense$2.13M$2.94M$1.76M$1.87M$1.80M$1.49M$2.54M$4.23M
Operating income-$2.96M-$3.51M-$2.23M-$2.95M-$2.45M-$2.65M-$3.62M-$5.86M
Interest expense$259,000$295,000$304,000$391,000$581,000$149,000$124,000$132,000
Net income-$3.14M-$3.79M-$3.02M-$4.17M-$3.28M-$2.79M-$3.71M-$5.97M
EBITDA-$2.68M-$2.95M-$2.22M-$2.94M-$2.27M-$2.64M-$3.61M-$5.85M
EPS (basic)-0.21-0.43-0.69—-1.57-3.68-0.05—
EPS (diluted)-0.21-0.43-0.69—-1.57-3.68-0.05—
Weighted avg. shares (diluted)32.49M17.12M4.35M—2.09M759,289703,298—
Balance sheet
Cash & equivalents$6.89M$9.90M$5.82M$2.98M$2.35M$476,000$898,000$1.70M
Short-term investments$61,000$64,000$63,000$62,000$62,000$359,000$1.35M$2.28M
Receivables———$7,000————
Current assets$7.34M$10.43M$6.21M$3.29M$2.58M$1.02M$2.58M$4.18M
PP&E, net$49,000$54,000$62,000$71,000$80,000$89,000$98,000$108,000
Intangibles$1.76M$1.71M$1.66M$1.66M$2.04M$2.17M$2.27M$2.59M
Total assets$9.75M$12.73M$8.59M$5.78M$5.49M$4.13M$6.25M$8.61M
Current liabilities$2.67M$4.95M$6.14M$6.22M$4.04M$10.39M$9.77M$9.54M
Short-term debt$1.44M$3.62M$4.00M$3.55M$1.88M$2.29M$1.95M$2.31M
Long-term debt$1.44M$3.62M$210,000$927,000—$2.72M$2.39M$2.81M
Total debt$2.87M$7.24M$4.21M$4.48M—$5.01M$4.34M$5.11M
Total liabilities$2.67M$4.99M$6.46M$15.56M$11.57M$10.68M$10.11M$9.93M
Shareholders' equity$7.08M$7.74M$2.12M-$9.78M-$6.08M-$6.55M-$3.86M-$1.32M
Net debt-$4.01M-$2.66M-$1.60M$1.49M—$4.54M$3.44M$3.41M
Shares outstanding39.89M28.99M8.22M3.07M2.76M764,18872.29M655,262
Cash flow statement
Operating cash flow-$2.93M-$4.59M-$2.72M-$1.99M-$5.08M-$1.53M-$2.36M-$3.96M
Capital expenditure———————$0
Free cash flow———————-$3.96M
Investing cash flow-$83,000-$112,000-$37,000-$95,000$296,000$754,000$898,000$3.70M
Financing cash flow$1,000$8.79M$5.59M$2.72M$6.65M$355,000$660,000$1.04M
Depreciation & amortization$281,000$562,000$9,000$9,000$182,000$9,000$10,000$9,000
Stock-based compensation—$0$0$0$0$0$60,000$196,000

Free plan shows the latest 8 periods; Pro shows all 67 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.